Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer

Summary: Chemo-/radiotherapy resistance is the main cause accounting for most treatment failure in colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo-/radiotherapy resistance. The underlying regulation mechanism of TICs in CRC remains unclear. Here we discove...

Full description

Bibliographic Details
Main Authors: Dengbo Ji, Tiancheng Zhan, Ming Li, Yunfeng Yao, Jinying Jia, Haizhao Yi, Meng Qiao, Jinhong Xia, Zhiqian Zhang, Huirong Ding, Can Song, Yong Han, Jin Gu
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Stem Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213671118304387
id doaj-585adf5fa9e34549863c3454e1f763c0
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Dengbo Ji
Tiancheng Zhan
Ming Li
Yunfeng Yao
Jinying Jia
Haizhao Yi
Meng Qiao
Jinhong Xia
Zhiqian Zhang
Huirong Ding
Can Song
Yong Han
Jin Gu
spellingShingle Dengbo Ji
Tiancheng Zhan
Ming Li
Yunfeng Yao
Jinying Jia
Haizhao Yi
Meng Qiao
Jinhong Xia
Zhiqian Zhang
Huirong Ding
Can Song
Yong Han
Jin Gu
Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
Stem Cell Reports
author_facet Dengbo Ji
Tiancheng Zhan
Ming Li
Yunfeng Yao
Jinying Jia
Haizhao Yi
Meng Qiao
Jinhong Xia
Zhiqian Zhang
Huirong Ding
Can Song
Yong Han
Jin Gu
author_sort Dengbo Ji
title Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
title_short Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
title_full Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
title_fullStr Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
title_full_unstemmed Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer
title_sort enhancement of sensitivity to chemo/radiation therapy by using mir-15b against dclk1 in colorectal cancer
publisher Elsevier
series Stem Cell Reports
issn 2213-6711
publishDate 2018-12-01
description Summary: Chemo-/radiotherapy resistance is the main cause accounting for most treatment failure in colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo-/radiotherapy resistance. The underlying regulation mechanism of TICs in CRC remains unclear. Here we discovered that miR-15b expression positively correlated with therapeutic outcome in CRC. Expression of miR-15b in pretreatment biopsy tissue samples predicted tumor regression grade (TRG) in rectal cancer patients after receiving neoadjuvant radiotherapy (nRT). Expression of miR-15b in post-nRT tissue samples was associated with therapeutic outcome. DCLK1 was identified as the direct target gene for miR-15b and its suppression was associated with self-renewal and tumorigenic properties of DCLK1+ TICs. We identified B lymphoma Mo-MLV insertion region l homolog (BMI1) as a downstream target regulated by miR-15b/DCLK1 signaling. Thus, miR-15b may serve as a valuable marker for prognosis and therapeutic outcome prediction. DCLK1 could be a potential therapeutic target to overcome chemo-/radioresistance in CRC. : Gu et al. identified that DCLK1 regulates the behavior of CRC TIC and is associated with chemo-/radiotherapy resistance. Expression of DCLK1 reversely correlated with prognosis and chemo-/radiotherapeutic outcome in CRC. miR-15b is able to sensitize the tumor cells to chemo-/radiotherapy by targeting DCLK1. miR-15b is a favorite factor for the prognosis and chemo-/radiotherapeutic outcome in clinical samples. Keywords: colorectal cancer, chemo-/radiotherapy, miR-15b, DCLK1
url http://www.sciencedirect.com/science/article/pii/S2213671118304387
work_keys_str_mv AT dengboji enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT tianchengzhan enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT mingli enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT yunfengyao enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT jinyingjia enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT haizhaoyi enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT mengqiao enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT jinhongxia enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT zhiqianzhang enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT huirongding enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT cansong enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT yonghan enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
AT jingu enhancementofsensitivitytochemoradiationtherapybyusingmir15bagainstdclk1incolorectalcancer
_version_ 1725266530757771264
spelling doaj-585adf5fa9e34549863c3454e1f763c02020-11-25T00:46:09ZengElsevierStem Cell Reports2213-67112018-12-0111615061522Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal CancerDengbo Ji0Tiancheng Zhan1Ming Li2Yunfeng Yao3Jinying Jia4Haizhao Yi5Meng Qiao6Jinhong Xia7Zhiqian Zhang8Huirong Ding9Can Song10Yong Han11Jin Gu12Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaDepartment of Cell Biology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaCentral Laboratory, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, ChinaSchool of Life Sciences, Tsinghua University, Beijing 100084, China; Peking-Tsinghua Center for Life Sciences, Beijing 100084, ChinaDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, ChinaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China; Peking-Tsinghua Center for Life Sciences, Beijing 100084, China; Peking University S.G. Hospital, Beijing 100144, China; Corresponding authorSummary: Chemo-/radiotherapy resistance is the main cause accounting for most treatment failure in colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo-/radiotherapy resistance. The underlying regulation mechanism of TICs in CRC remains unclear. Here we discovered that miR-15b expression positively correlated with therapeutic outcome in CRC. Expression of miR-15b in pretreatment biopsy tissue samples predicted tumor regression grade (TRG) in rectal cancer patients after receiving neoadjuvant radiotherapy (nRT). Expression of miR-15b in post-nRT tissue samples was associated with therapeutic outcome. DCLK1 was identified as the direct target gene for miR-15b and its suppression was associated with self-renewal and tumorigenic properties of DCLK1+ TICs. We identified B lymphoma Mo-MLV insertion region l homolog (BMI1) as a downstream target regulated by miR-15b/DCLK1 signaling. Thus, miR-15b may serve as a valuable marker for prognosis and therapeutic outcome prediction. DCLK1 could be a potential therapeutic target to overcome chemo-/radioresistance in CRC. : Gu et al. identified that DCLK1 regulates the behavior of CRC TIC and is associated with chemo-/radiotherapy resistance. Expression of DCLK1 reversely correlated with prognosis and chemo-/radiotherapeutic outcome in CRC. miR-15b is able to sensitize the tumor cells to chemo-/radiotherapy by targeting DCLK1. miR-15b is a favorite factor for the prognosis and chemo-/radiotherapeutic outcome in clinical samples. Keywords: colorectal cancer, chemo-/radiotherapy, miR-15b, DCLK1http://www.sciencedirect.com/science/article/pii/S2213671118304387